|
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief Communication |
1 New York University School of Medicine, New York, New York; 2 Nathan Kline Institute, New York, New York; 3 University of Florence, Florence, Italy; 4 University of Munich, Munich, Germany; and 5 University of Washington, Seattle, Washington
Correspondence: For correspondence contact: Lisa Mosconi, PhD, Center for Brain Health of the Silberstein Institute, Department of Psychiatry, NYU School of Medicine, 560 First Ave., New York NY, 10016. E-mail: lisa.mosconi{at}med.nyu.edu
The normative reference sample is crucial for the diagnosis of Alzheimer's disease (AD) with automated 18F-FDG PET analysis. We tested whether an 18F-FDG PET database of longitudinally confirmed healthy elderly individuals ("normals," or NLs) would improve diagnosis of AD and mild cognitive impairment (MCI). Methods: Two 18F-FDG PET databases of 55 NLs with 4-y clinical follow-up examinations were created: one of NLs who remained NL, and the other including a fraction of NLs who declined to MCI at follow-up. Each 18F-FDG PET scan of 19 NLs, 37 MCI patients, and 33 AD patients was z scored using automated voxel-based comparison to both databases and examined for AD-related abnormalities. Results: Our database of longitudinally confirmed NLs yielded 1.4- to 2-fold higher z scores than did the mixed database in detecting 18F-FDG PET abnormalities in both the MCI and the AD groups. 18F-FDG PET diagnosis using the longitudinal NL database identified 100% NLs, 100% MCI patients, and 100% AD patients, which was significantly more accurate for MCI patients than with the mixed database (100% NLs, 68% MCI patients, and 94% AD patients identified). Conclusion: Our longitudinally confirmed NL database constitutes reliable 18F-FDG PET normative values for MCI and AD.
Key Words: neurology PET Alzheimer's disease normative reference database early diagnosis
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
P. B. Rosenberg and A. E. Hillis Biomarkers for Alzheimer's disease: ready for the next step Brain, August 1, 2009; 132(8): 2002 - 2004. [Full Text] [PDF] |
||||
![]() |
L. Mosconi, R. Mistur, R. Switalski, M. Brys, L. Glodzik, K. Rich, E. Pirraglia, W. Tsui, S. De Santi, and M. J. de Leon Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease Neurology, February 10, 2009; 72(6): 513 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Patterson, D. L. Lilien, A. Takalkar, R. E. Kelley, and A. Minagar Potential Value of Quantitative Analysis of Cerebral PET in Early Cognitive Decline American Journal of Alzheimer's Disease and Other Dementias, January 1, 2009; 23(6): 586 - 592. [Abstract] [PDF] |
||||
![]() |
L. Mosconi, W. H. Tsui, K. Herholz, A. Pupi, A. Drzezga, G. Lucignani, E. M. Reiman, V. Holthoff, E. Kalbe, S. Sorbi, et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias J. Nucl. Med., March 1, 2008; 49(3): 390 - 398. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |